SHARIF
Pharmaceuticals Ltd.

Zenosyn

Naproxen

COMPOSITION :
Zenosyn tablet : Each enteric coated tablet contains Naproxen Sodium USP equivalent to Naproxen 500 mg.

PHARMACOLOGY :
Zenosyn is a Non-Steroidal Anti-inflammatory agent. The drug exhibits anti-inflammatory, analgesic and antipyretic activity by inhibiting prostaglandin synthesis. **Zenosyn** is completely absorbed from the GIT but the peak plasma concentration is attained about 2-4 hours after ingestion.

THERAPEUTIC INDICATIONS :
Naproxen is indicated for the relief of symptoms of rheumatoid arthritis, both of acute flares and long term management of the disease. It is also used in the diseases of

- Rheumatoid osteoarthritis (degenerative arthritis)
- Ankylosing spondylitis
- Juvenile rheumatoid arthritis
- Tendinitis
- Bursitis
- Acute gout
- Acute musculoskeletal disorders (such as sprains direct trauma and fibrositis),
- Migraine and dysmenorrhea.

DOSAGE AND ADMINISTRATION :
For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis: The usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.
For acute gout: 750 mg should be given initially, followed by 500 mg 8 hoursly and thereafter 250 mg at 12 hours intervals until the attack has passed.
For dysmenorrhea: 500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.
For analgesia and acute musculoskeletal disorders: 500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.

PRECAUTIONS & CONTRAINDICATIONS :
Naproxen should be used with caution in patients with cardiac, hepatic and renal impairment, coagulation defect and previous history of gastro-intestinal ulceration. The drug is contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID - which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

DRUG INTERACTIONS :
Use in patients receiving ACE inhibitors may potentiate renal diseases. Drug which are Albumin-bound may be displaced from their binding sites as a result of the naproxen anions' affinity for protein. Use with caution when given concomitantly with coumarin type anticoagulants, hydantoin sulfonamides, or sulfonylureas. Concomitant administration is not recommended because reduction in the antihypertensive effect of propranolol and other beta-blockers may occur. Concurrent administration of probenecid or methotrexate should be done cautiously to prevent potential naproxen and methotrexate toxicity, respectively.

USE IN PREGNANCY & LACTATION :
There are no well controlled studies in pregnant women. The drug should not be used during pregnancy unless clearly needed. Because of the possible adverse effects of prostaglandin inhibiting drugs on neonates, use in nursing mothers must be avoided.

UNDESIRABLE EFFECTS :
Gastro-intestinal discomfort - nausea, diarrhoea, occasional bleeding and ulceration. Hypersensitivity reactions - notably with bronchospasm, angioedema and rashes, drowsiness, headache, vertigo, tinnitus.

STORAGE :
Store in cool and dry place, away from light. Keep out of the reach of children.

COMMERCIAL PACK :
Zenosyn Tablet : Each commercial box contains 3x10 tablets in Alu-PVC blister pack.

Manufactured By :

Sharif Pharmaceuticals Ltd.
Rupganj, Narayanganj, Bangladesh.

P12014

SHARIF
Pharmaceuticals Ltd.

‡R‡bwwmb

b¨v‡cv‡·b

Dcv`vb t
†R‡bwwmb U¨ve‡jU t cvZvU G‡pUvwiK †Kv‡UW U¨ve‡j‡U Av‡Q b¨v‡c‡·b †mwWqvg BDGmvc hv b¨v‡c‡·b 500 vg.Mv. Gi mgZj¨|

dvg‡KvjvR t
‡R‡bwwmb GKvU NSAID Jla| GB Jla †cv÷v‡MÖwWb Drcv`‡b evav `vb Kivi gva¨‡g c`vn‡ivax, Ri vbeviY I e¨_v ckgY Kvh¶gZv c`kb K‡i| MjvatKi‡Yi cici B ‡R‡bwwmb m¤cYi‡c i‡³ †kwlZ nq| vKš 2-4 NvUv ci GvU m‡ev”P cvRgv Nb‡Z †cŠQvq|

‡ivM vb‡`kbv t
‡R‡bwwmb evZRvbZ †ivM †hgb Zxe evZ I `xN¨vqx evZ Gi vPvKrmvq vb‡`vkZ| GQvovI Av¨ msvké e¨_v, A¨vbKvB‡jwRs ¯úbWvBwjvUm, R‡fbvBj viDgvU‡qW Avi_vBvUm, †UbWvBivbvUm, evivmvBvUm, †ckvi c`vn, gvB‡M‡bi e¨_v I vWm‡g‡bwiqvq vb‡`vkZ|

gvÎv I †mebvevwa t
wiDgvU‡qW Avi_vBvUm, Av÷I Avi_vBvUm I A¨vbKvB‡jwRs ¯úbWvBwjvUm t ‰`vbK 500-1000 vg.Mv. 2 evi 12 NvUv cici LvIqvi ci|
Zxe evZ t cv_vgKfv‡e 750 vg.Mv., Gici 500 vg.Mv. cvZ 6-8 NvUv cici Ges cieZ‡Z 250 vg.Mv. K‡i cvZ 12 NvUv cici hZ¶Y DcmM cvijv¶Z nq|
vWm‡g‡bwiqv t cv_vgKfv‡e 500 vg.Mv., Gici 250 vg.Mv. K‡i cvZ 6-8 NvUv cici 5 v`b chš|
Av¯ msvké e¨_v t cv_vgKfv‡e 500 vg.Mv., Gici 250 vg.Mv. K‡i cvZ 6-8 NvUv cici hZ¶Y DcmM cvijv¶Z nq|

cvkcvZvµqv t
cvkcvZvµqvi g‡a¨ i‡q‡Q, evg evg fve, WvqviqvI, AwšK Avjmvi, kvmKó, GbvRIBvWgv, PvKv PvKv `vM, vSgvb, gv_v e¨_v, gv_v †Nvivi, vUvbUvm BZ¨vw`|

mZKZv I cvZvb‡`kbv t
hv‡`i †ccvUK Avjmvi Av‡Q vKsev hv‡`i A‡š i³¶i‡Yi j¶Y Av‡Q Zv‡`i †¶‡Î e¨envi Kiv hv‡e bv| hv‡`i gvSvix †_‡K Zxe iK‡gi vKWbx mgm¨v ve`¨gvb Zv‡`i †¶‡Î e¨envi Kiv hv‡e bv| b¨v‡c‡·b †mwWqv‡gi cvZ AvZms‡e`bkvj †ivMv‡`i †¶‡ÎI e¨envi Kiv hv‡e bv| A¨vmvcvib vKsev Ab¨ †Kvb bb-†÷iqWvj Jla e¨en‡ii d‡j hv‡`i A¨vRgv te‡o hvq vKsev Zxe ivBbvBvUm ev Zxe AwUKwiqv †`Lv hvq Zv‡`i †¶‡Î e¨envi Kiv hv‡e bv|

Jla vg_v¯qv t
ACE Bbwmvevi e¨enviKvi‡`i †¶‡Î b¨v‡c‡·b †mwWqvg e¨envi Ki‡j gÎ †ivM †`Lv v`‡Z c‡i| b¨v‡c‡·b †mwWqvg Kgvib RvZxq GvbU-†Kvqv¸‡jvU, nvB‡WbUvqb, mvj‡dvbvBj BDwiqv I mvj‡dvbvgvB‡Wi m‡_ mveavbZvi m‡_ e¨envi Kiv DvPZ| GQvovI †cvcvbjj I veUv eKvi Gi KvhKwiZv Kvg‡q †`evi ceYZv b¨v‡c‡·b †mwWqv‡gi †¶‡Î cvijv¶Z nq| vg‡_vU‡·U I c‡e‡bwmW Gi m‡_ m¤ve¨ velvµqv Gov‡bvi Rb¨ Gi e¨envi mveavbZvi m‡_ Kiv DvPZ|

Mfve¯vq I ¯b¨`vbK‡j e¨envi t
GKvšB eva¨ bv n‡j Mfve¯vq I ¯b¨`vbK‡j GUv †`qv h‡e bv|

msi¶Y t
Av‡jv †_‡K `‡i, vvÛv, i®v ¯v‡b I wkï‡`i bvM‡ji evB‡i ivLb|

ewYvR¨K †gvoK t
‡R‡bwwmb U¨ve‡jU t cvZvU e‡· Av‡Q 3 × 10 vU U¨ve‡jU G¨v‡j-vcvfvm veévi c¨v‡K|

c¯ZKviK t

kixd dvgwmDvUK¨vjm vjt
i‡cMÄ, bvivqbMÄ, evsjv‡`k|

P12014